comparemela.com

Latest Breaking News On - Arie belldegrun - Page 1 : comparemela.com

Allogene Therapeutics, Inc (NASDAQ:ALLO) Given Consensus Recommendation of Moderate Buy by Analysts

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month […]

Switzerland generalArie belldegrunPiper sandlerJpmorgan chase coSecurities exchange commissionRoyal bankSg americas securitiesAllogene therapeutics incCitigroup incSwiss national bankAlps advisors incAllogene therapeuticsGet free reportDirector arie belldegrunExchange commissionNational bank

Allogene Therapeutics (NASDAQ:ALLO) Now Covered by Analysts at Piper Sandler

Piper Sandler initiated coverage on shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) in a report published on Friday, Marketbeat reports. The brokerage issued an overweight rating and a $11.00 target price on the stock. ALLO has been the subject of several other research reports. Royal Bank of Canada reissued an outperform rating and issued […]

United statesStifel nicolausPiper sandlerArie belldegrunVictory capital management incHarbor capital advisors incVontobel holding ltdAllogene therapeutics incRoyal bankJpmorgan chase coPrincipal financial group incSecurities exchange commissionAllogene therapeuticsFree reportModerate buyGet free report

If You Can Only Buy One Penny Stock in May, It Better Be One of These 3 Names

Penny stocks to buy carry a great deal of risk. However, there are a few that look interesting after due diligence.

United kingdomArie belldegrunDavid desharnaisGary kremenSteven humphreysDavid changRobert bermanAdvanced micro devicesExecutive officer steven humphreysRekor systemsRekor oneTransportation data managementChairman robert bermanAllogene therapeuticsChief executive officerPenny stocks

Insider Trading: Allogene Therapeutics Insider Buys Shares Worth $5M

Arie Belldegrun, a director and more-than-10% owner of Allogene Therapeutics (NASDAQ:ALLO), bought shares worth $4.99 million on May 16, 2024, show.

Arie belldegrunAllogene therapeutics

Kyverna eyes $180M IPO haul to fund autoimmune CAR-T trials

Kyverna eyes $180M IPO haul to fund autoimmune CAR-T trials
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Arie belldegrunGilead sciencesNational institutes of healthKyverna therapeuticsVida venturesKite pharmaNational institutes

vimarsana © 2020. All Rights Reserved.